Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 29, 2022 12:16 ET | Source: Evaxion Biotech

Evaxion Biotech to Host Q1 2022 Corporate Update Conference Call & Webcast on May 11

COPENHAGEN, Denmark, April 29, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
April 06, 2022 07:30 ET | Source: Evaxion Biotech

Evaxion Biotech Hosting Key Opinion Leader Webinar on Metastatic Melanoma and Personalized Cancer Immunotherapies

Tuesday, April 12th @ 12:30 pm ET COPENHAGEN, Denmark, April 06, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company...
March 22, 2022 06:30 ET | Source: Evaxion Biotech

Evaxion Biotech Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Completed follow-on public offering (FPO) of 3,942,856 ordinary shares represented by American Depositary Shares (ADSs) raising net proceeds of $24.9 million after deducting underwriting discounts,...
March 14, 2022 07:00 ET | Source: Evaxion Biotech

Evaxion Biotech Strengthens Management Team with Two Senior Appointments

COPENHAGEN, Denmark, March 14, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) is a clinical-stage biotechnological company specializing in the development of AI-powered immunotherapies...
March 07, 2022 07:30 ET | Source: Evaxion Biotech

Evaxion Biotech Completes Recruitment for Phase 1/2a Clinical Trial for EVX-02

COPENHAGEN, Denmark, March 07, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, has...
January 26, 2022 07:30 ET | Source: Evaxion Biotech

Evaxion Biotech Announces Publication of Clinical Data of EVX-01 Heading into Phase 2b in Collaboration with Merck

COPENHAGEN, Denmark, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to...
January 18, 2022 08:00 ET | Source: Evaxion Biotech

Evaxion Biotech Receives Regulatory Clearance to Initiate Phase 2 Trial of EVX-01 in Combination with KEYTRUDA® for Treatment of Melanoma

COPENHAGEN, Denmark, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to...
November 09, 2021 17:00 ET | Source: Evaxion Biotech

Evaxion Biotech Announces Closing of $27.6 Million Follow-on Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

COPENHAGEN, Denmark, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
November 09, 2021 06:30 ET | Source: Evaxion Biotech

Evaxion Biotech Announces Q3 2021 Financial Results and Provides Business Update

Expect to close our follow-on public offering (FPO) of 3,942,856 ordinary shares represented by American Depositary Shares (ADSs) for gross proceeds of $27.6 million before deducting underwriter fees...
November 05, 2021 06:00 ET | Source: Evaxion Biotech

Evaxion Biotech Announces Pricing of $24.0 Million Follow-on Public Offering

COPENHAGEN, Denmark, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...